TwoOncDocs@TwoOncDocs

🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi

podcasts.apple.com/us/podcas…
Joined June 2022
75 Photos and videos
🤔 Heading to #ASH26? ⭐️ Join us for a complimentary in-person Hematology Board Review for fellows & anyone prepping for boards 🩸 📅 Friday, December 11, 2026 🕗 8:00 AM–12:00 PM CT 📍 420 Julia St., New Orleans, LA 🔗 Register: bit.ly/hemeboards
Made with AI
1
10
26
2,782
Today 9/24/26 new approval in 2L clear cell mRCC with some caveats #LITESPARK011 💢 4mo PFS gain, higher ORR (53% vs 40%) & DOR (23 v 12mo) 💢 OS is not yet significant 💢 how does it perform post 1L IO/IO vs IO/TKI, weight of extra toxicity & optimal sequencing still unclear
Oncology Brothers
@OncBrothers
Sep 24
Based off LITESPARK-011: Belzutifan + Lenvatinib is now @FDA ✅ in 2L RCC after IO exposure: PhIII: Bel + Len vs. Cabo - mPFS 14.6mos vs. 10.7mos (HR: 0.74) - mOS 33.7mos vs. 28.6mos (HR: 0.85, p=0.061). - AEs: 72% vs. 66% w/ Gr ≥ 3 #OncTwitter #gusm @OncUpdates
1
10
18
2,155
TwoOncDocs retweeted
Paul H, PharmD, RPH@phsiao4
Sep 12
Highly recommended: @TwoOncDocs Yes for Pharmacy students as well
OncLive.com
@OncLive
Sep 11
Localized NSCLC in 2026: new staging, expanded perioperative options, and a driver-directed pathway that reshapes management. The Two Onc Docs deliver the high-yield takeaways, tune in now! 🎙️Full episode: hubs.li/Q04xhhFv0
1
3
5
657
So exciting to see the FDA approval for this today ‼️‼️
TwoOncDocs@TwoOncDocs
May 31
Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹 #RASolute today presented at #ASCO26: Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ +w/o RAS (mOS 13.2 mo vs. 6.6 mo) A HUGE advance in one of the most lethal cancers 💜
2
6
1,236
New episode out today updating Iron Overload Syndromes! 🩸 A 52M is found to have an elevated ferritin and a transferrin saturation of 60%. Genetic testing confirms C282Y homozygosity. Which is the most appropriate 1L treatment? @HemOncFellows #hematology #boardreview
14% Deferasirox
83% Therapeutic phlebotomy
3% Deferoxamine
0% Liver transplantation
35 votes • Final results
1
1
5
1,295
The answer is B) Phlebotomy is 1L for HFE hereditary hemochromatosis, w/ target ferritin of 50–100 μg/L then maintenance near ~50 μg/L.  Oral/parenteral chelators (deferasirox, deferoxamine) -> for those who cannot tolerate phlebotomy or have 2ary/transfusional iron overload
188
TwoOncDocs retweeted
Simon C
@scserendipity1
Aug 9
Great work Well worth listening to @OpenMedicineHQ
TwoOncDocs@TwoOncDocs
Jul 14
Burnout is extremely prevalent in medicine & specifically in oncology - in this week’s episode we discuss Wellness in Oncology tips w/ @doclauravater & the SMILE Scale - a wellness behavioral tool designed to measure and encourage healthy habits ❤️‍🩹 podcasts.apple.com/us/podcas…
3
3
746
We love ourselves a @thefellowoncall x @TwoOncDocs! Thank you @wimedicineorg #COSMO2026 for inviting us to present our workshop “Build, Connect, Rise: Education, Mentorship and Career Development in the Digital Age of Oncology”!
1
3
12
1,267
RT @DrKarineTawagi: 📣 FDA approval of Pluvicto triplet vs ADT/ARPI for mCSPC (APMS) vs ADT/ARPI #PSMAddition ✔️ rPFS: HR 0.72 ✔️ time to m…
2
39
TwoOncDocs retweeted
OncLive.com
@OncLive
Jul 27
🎙️ New episode alert: Samantha A. Armstrong, MD, and Karine Tawagi, MD break down DLBCL presentation on Two Onc Docs, from classic B symptoms to the 30-40% of cases with GI, CNS, or thyroid involvement, and why excisional biopsy is required. 🔬 Access the full OncLive® episode: hubs.li/Q04qyRzH0 @TwoOncDocs @SamArmstrongMD @DrKarineTawagi #DLBCL #Lymphoma #HemOnc
2
8
1,309
Burnout is extremely prevalent in medicine & specifically in oncology - in this week’s episode we discuss Wellness in Oncology tips w/ @doclauravater & the SMILE Scale - a wellness behavioral tool designed to measure and encourage healthy habits ❤️‍🩹 podcasts.apple.com/us/podcas…
1
1
14
1,639
A few months after ASCO GU, EVP is now FDA approved for cisplatin-eligible MIBC! 🎉 Now many trials looking at bladder preservation in pts w/ cCR inc: 🌟 HCRN GU22-598 ph2 @hoosiercancer 🌟 EV-PRIME @koshkin85 EVP+RT 🌟 CONSOLIDATE @OAlhalabiMD EVP+ RT 🌟 Astellas 7465 ph2
Karine Tawagi MD@DrKarineTawagi
Feb 27
Groundbreaking KN-B15 for EVP in cis-eligible MIBC 👤 most T3/T4a, 90% pure urothelial 🎖️ EFS HR 0.53, OS HR 0.65, pCR 55.8% vs 32.5% ⚠️¾ grade 3 TEAE, 25% stopped NA EVP & 28.6% adj EVP d/t TEAE ‼️36% neuropathy, 63% skin, 23% 👁️ ❓how many got IO in control arm
9
28
4,044
Welcome to all starting fellowship today!🎉 Remember it’s normal to feel overwhelmed (juggling call, studying for ABIM, sheer amount of new info to know), we are all a work in progress, it’s ok to ask for help Next week’s episode w/ @doclauravater will cover wellness tips🧡
1
3
20
950
TwoOncDocs retweeted
Paul H, PharmD, RPH@phsiao4
Jun 29
Nice episode @TwoOncDocs I even encouraged my MD daughter( just started her OBGyn residency) to set up a goal for getting to know at least one Inpatient Pharmacist next few weeks. Definitely the best resource (drug related issues) podcasts.apple.com/us/podcas…
Paul H, PharmD, RPH@phsiao4
Jun 19
FaceTimed my MD daughter earlier. I suggested her to get to know at least one inpatient pharmacist on first name basis and be respectful to own hospital Formulary system. Learn drug cost if possible and be cost conscious. Residency starts Monday officially Good Luck!
1
5
757
Our newest episode out today with @doclauravater on the transition from fellow to attending & mistakes she made as a new attending physician (so you don’t have to) It really hit home for a lot of us, with tips on managing each of these 🫶🏼 podcasts.apple.com/us/podcas…
2
10
20
3,874
This week, we released an update on the #SARC041 trial from #ASCO26 plenary 🤩 ➡️ ph3 trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS) Next week, we have an extremely special guest & friend for a new 2 part series!! @doclauravater
TwoOncDocs@TwoOncDocs
May 31
🤩SARCOMA AT PLENARY!🎗️ 🔹 SARC041 provides the first randomized validation of CDK4 inhibition in DDLPS 📈 mPFS: 9.7 vs 1.5 mo (HR 0.39, p<0.001) — >6× improvement 🎯 ORR: 9.3% vs 0% ⏳ OS trend favors abemaciclib (HR 0.55) 🔄 Crossover activity confirmed (mPFS 3.4 mo) #ASCO26
2
3
6
1,173
🚨Join the @ASCO #IMGCoP Summer 2026 Webinar Series! "Fireside Chat with Fellowship Program Directors" on 6/23 6-7 PM CST with @KArnaoutakis #DrJanakiSharma @DrKarineTawagi @ASridharMD Register tinyurl.com/bhdf788h @ASCOTECAG @HemOncFellows #MedTwitter #MedEd #IMG
3
10
23
7,640
Join us 6/23 for a webinar with heme/onc PDs on what makes a successful heme/onc candidate & eventually fellow 💫
This tweet is unavailable
4
8
804
TwoOncDocs retweeted
Antonio Ocejo
@ja_ocejo
Jun 12
📣 Oncology fellows: Applications are open for the 2026–2027 FDA/ASCO Fellows’ Day Workshop! Great way to learn from FDA oncology leaders about trial design, regulatory science, and the drug/device approval process through case-based discussions and Q&A. 📌Open to oncology fellows with at least one year of completed training. 🗓️ In-person + virtual options available, with up to $500 reimbursement for selected in-person participants. Apply by June 26: asco.smapply.org/ @ASCOTECAG @HemOncFellows @IMG_Oncologists
1
13
42
3,730
TwoOncDocs retweeted
Ria Kraft, MD@riakraftmd
May 28
It’s #radonc away rotation season! For #medstudents and junior #residents, here are my go-to resources in radiation oncology (1/2).
4
31
102
6,984
Load more